nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—ABCG2—Leflunomide—systemic scleroderma	0.0704	0.147	CbGbCtD
Imatinib—ABCG2—Mycophenolate mofetil—systemic scleroderma	0.0435	0.0911	CbGbCtD
Imatinib—ALB—Captopril—systemic scleroderma	0.0381	0.0798	CbGbCtD
Imatinib—ABCA3—alveolus of lung—systemic scleroderma	0.0314	0.269	CbGeAlD
Imatinib—CYP1A2—Pentoxifylline—systemic scleroderma	0.0304	0.0638	CbGbCtD
Imatinib—ALB—Mycophenolate mofetil—systemic scleroderma	0.03	0.0628	CbGbCtD
Imatinib—CYP1A2—Leflunomide—systemic scleroderma	0.029	0.0608	CbGbCtD
Imatinib—ABCB1—Lisinopril—systemic scleroderma	0.0266	0.0557	CbGbCtD
Imatinib—CYP2C9—Leflunomide—systemic scleroderma	0.0262	0.0548	CbGbCtD
Imatinib—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.0241	0.0505	CbGbCtD
Imatinib—ALB—Prednisone—systemic scleroderma	0.024	0.0502	CbGbCtD
Imatinib—ABCB1—Captopril—systemic scleroderma	0.0199	0.0417	CbGbCtD
Imatinib—CYP2D6—Captopril—systemic scleroderma	0.0188	0.0393	CbGbCtD
Imatinib—ABCG2—Methotrexate—systemic scleroderma	0.0174	0.0365	CbGbCtD
Imatinib—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0157	0.0329	CbGbCtD
Imatinib—CYP2C19—Prednisone—systemic scleroderma	0.0155	0.0326	CbGbCtD
Imatinib—ABCB1—Prednisone—systemic scleroderma	0.0125	0.0263	CbGbCtD
Imatinib—ALB—Methotrexate—systemic scleroderma	0.012	0.0252	CbGbCtD
Imatinib—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.00939	0.0197	CbGbCtD
Imatinib—KIT—myenteric nerve plexus—systemic scleroderma	0.00885	0.0759	CbGeAlD
Imatinib—CYP2C9—cardial valve—systemic scleroderma	0.00777	0.0666	CbGeAlD
Imatinib—CYP3A4—Prednisone—systemic scleroderma	0.00751	0.0157	CbGbCtD
Imatinib—ABCB1—Methotrexate—systemic scleroderma	0.00629	0.0132	CbGbCtD
Imatinib—Nilotinib—BLK—systemic scleroderma	0.00488	1	CrCbGaD
Imatinib—DDR1—smooth muscle tissue—systemic scleroderma	0.00235	0.0201	CbGeAlD
Imatinib—KIT—endothelium—systemic scleroderma	0.00196	0.0168	CbGeAlD
Imatinib—ABCA3—tendon—systemic scleroderma	0.00191	0.0164	CbGeAlD
Imatinib—KIT—blood vessel—systemic scleroderma	0.00181	0.0155	CbGeAlD
Imatinib—PDGFRB—blood vessel—systemic scleroderma	0.00177	0.0152	CbGeAlD
Imatinib—DDR1—tendon—systemic scleroderma	0.00177	0.0151	CbGeAlD
Imatinib—ABCA3—lung—systemic scleroderma	0.00168	0.0144	CbGeAlD
Imatinib—DDR1—lung—systemic scleroderma	0.00155	0.0133	CbGeAlD
Imatinib—CA3—connective tissue—systemic scleroderma	0.00151	0.013	CbGeAlD
Imatinib—CA7—digestive system—systemic scleroderma	0.00119	0.0102	CbGeAlD
Imatinib—PDGFRA—connective tissue—systemic scleroderma	0.00116	0.00996	CbGeAlD
Imatinib—ABL2—tendon—systemic scleroderma	0.00115	0.00987	CbGeAlD
Imatinib—PIP4K2C—tendon—systemic scleroderma	0.00109	0.00934	CbGeAlD
Imatinib—CA12—connective tissue—systemic scleroderma	0.00107	0.00919	CbGeAlD
Imatinib—PTGS1—artery—systemic scleroderma	0.00106	0.00913	CbGeAlD
Imatinib—PDGFRA—smooth muscle tissue—systemic scleroderma	0.00106	0.00911	CbGeAlD
Imatinib—CA9—digestive system—systemic scleroderma	0.00105	0.00897	CbGeAlD
Imatinib—CA3—tendon—systemic scleroderma	0.00104	0.00892	CbGeAlD
Imatinib—CSF1R—connective tissue—systemic scleroderma	0.00102	0.00877	CbGeAlD
Imatinib—ABL2—lung—systemic scleroderma	0.00101	0.00867	CbGeAlD
Imatinib—CA9—tendon—systemic scleroderma	0.000996	0.00854	CbGeAlD
Imatinib—PIP4K2C—lung—systemic scleroderma	0.000956	0.0082	CbGeAlD
Imatinib—CA14—tendon—systemic scleroderma	0.000945	0.0081	CbGeAlD
Imatinib—CSF1R—smooth muscle tissue—systemic scleroderma	0.000935	0.00802	CbGeAlD
Imatinib—KIT—connective tissue—systemic scleroderma	0.000928	0.00796	CbGeAlD
Imatinib—CSF1R—skin of body—systemic scleroderma	0.000923	0.00792	CbGeAlD
Imatinib—CA3—lung—systemic scleroderma	0.000913	0.00783	CbGeAlD
Imatinib—PDGFRB—connective tissue—systemic scleroderma	0.000907	0.00778	CbGeAlD
Imatinib—PTGS1—endothelium—systemic scleroderma	0.000899	0.00771	CbGeAlD
Imatinib—KIT—smooth muscle tissue—systemic scleroderma	0.000849	0.00728	CbGeAlD
Imatinib—LCK—lung—systemic scleroderma	0.000849	0.00728	CbGeAlD
Imatinib—PDGFRA—digestive system—systemic scleroderma	0.000839	0.00719	CbGeAlD
Imatinib—KIT—skin of body—systemic scleroderma	0.000838	0.00719	CbGeAlD
Imatinib—PDGFRB—smooth muscle tissue—systemic scleroderma	0.000829	0.00711	CbGeAlD
Imatinib—PTGS1—blood vessel—systemic scleroderma	0.000829	0.00711	CbGeAlD
Imatinib—PDGFRB—skin of body—systemic scleroderma	0.000819	0.00702	CbGeAlD
Imatinib—ABL1—connective tissue—systemic scleroderma	0.000808	0.00693	CbGeAlD
Imatinib—NQO2—tendon—systemic scleroderma	0.0008	0.00686	CbGeAlD
Imatinib—PDGFRA—tendon—systemic scleroderma	0.000798	0.00684	CbGeAlD
Imatinib—SLC22A2—digestive system—systemic scleroderma	0.000797	0.00683	CbGeAlD
Imatinib—CA12—digestive system—systemic scleroderma	0.000774	0.00664	CbGeAlD
Imatinib—ABL1—smooth muscle tissue—systemic scleroderma	0.000739	0.00634	CbGeAlD
Imatinib—CSF1R—digestive system—systemic scleroderma	0.000738	0.00633	CbGeAlD
Imatinib—ABL1—skin of body—systemic scleroderma	0.00073	0.00626	CbGeAlD
Imatinib—CSF1R—tendon—systemic scleroderma	0.000703	0.00603	CbGeAlD
Imatinib—NQO2—lung—systemic scleroderma	0.000702	0.00602	CbGeAlD
Imatinib—PDGFRA—lung—systemic scleroderma	0.0007	0.00601	CbGeAlD
Imatinib—SLC47A1—digestive system—systemic scleroderma	0.000674	0.00578	CbGeAlD
Imatinib—KIT—digestive system—systemic scleroderma	0.00067	0.00575	CbGeAlD
Imatinib—PDGFRB—digestive system—systemic scleroderma	0.000655	0.00562	CbGeAlD
Imatinib—CA12—lung—systemic scleroderma	0.000646	0.00554	CbGeAlD
Imatinib—SLC47A1—tendon—systemic scleroderma	0.000642	0.0055	CbGeAlD
Imatinib—PDGFRB—tendon—systemic scleroderma	0.000623	0.00534	CbGeAlD
Imatinib—CSF1R—lung—systemic scleroderma	0.000617	0.00529	CbGeAlD
Imatinib—CA1—digestive system—systemic scleroderma	0.000613	0.00526	CbGeAlD
Imatinib—ABL1—digestive system—systemic scleroderma	0.000584	0.00501	CbGeAlD
Imatinib—SLC47A1—lung—systemic scleroderma	0.000563	0.00483	CbGeAlD
Imatinib—KIT—lung—systemic scleroderma	0.00056	0.0048	CbGeAlD
Imatinib—ABL1—tendon—systemic scleroderma	0.000555	0.00476	CbGeAlD
Imatinib—CA2—connective tissue—systemic scleroderma	0.00055	0.00472	CbGeAlD
Imatinib—PDGFRB—lung—systemic scleroderma	0.000547	0.00469	CbGeAlD
Imatinib—ORM1—lung—systemic scleroderma	0.000513	0.0044	CbGeAlD
Imatinib—CA1—lung—systemic scleroderma	0.000512	0.00439	CbGeAlD
Imatinib—CA2—smooth muscle tissue—systemic scleroderma	0.000503	0.00432	CbGeAlD
Imatinib—CA2—skin of body—systemic scleroderma	0.000497	0.00426	CbGeAlD
Imatinib—ABCB1—blood vessel—systemic scleroderma	0.00049	0.0042	CbGeAlD
Imatinib—ABL1—lung—systemic scleroderma	0.000487	0.00418	CbGeAlD
Imatinib—CYP2C19—digestive system—systemic scleroderma	0.000434	0.00372	CbGeAlD
Imatinib—PTGS1—connective tissue—systemic scleroderma	0.000425	0.00364	CbGeAlD
Imatinib—CA2—digestive system—systemic scleroderma	0.000397	0.00341	CbGeAlD
Imatinib—PTGS1—smooth muscle tissue—systemic scleroderma	0.000389	0.00333	CbGeAlD
Imatinib—PTGS1—skin of body—systemic scleroderma	0.000384	0.00329	CbGeAlD
Imatinib—CA2—tendon—systemic scleroderma	0.000378	0.00324	CbGeAlD
Imatinib—CYP1A2—digestive system—systemic scleroderma	0.000354	0.00304	CbGeAlD
Imatinib—CYP3A5—digestive system—systemic scleroderma	0.000342	0.00293	CbGeAlD
Imatinib—CYP2C9—digestive system—systemic scleroderma	0.000336	0.00288	CbGeAlD
Imatinib—CA2—lung—systemic scleroderma	0.000332	0.00285	CbGeAlD
Imatinib—ABCG2—lung—systemic scleroderma	0.000307	0.00264	CbGeAlD
Imatinib—PTGS1—digestive system—systemic scleroderma	0.000307	0.00263	CbGeAlD
Imatinib—CYP1A2—lung—systemic scleroderma	0.000296	0.00254	CbGeAlD
Imatinib—PTGS1—tendon—systemic scleroderma	0.000292	0.00251	CbGeAlD
Imatinib—CYP3A5—lung—systemic scleroderma	0.000285	0.00245	CbGeAlD
Imatinib—CYP3A4—digestive system—systemic scleroderma	0.000256	0.0022	CbGeAlD
Imatinib—PTGS1—lung—systemic scleroderma	0.000256	0.0022	CbGeAlD
Imatinib—CYP2D6—digestive system—systemic scleroderma	0.000252	0.00216	CbGeAlD
Imatinib—ABCB1—digestive system—systemic scleroderma	0.000182	0.00156	CbGeAlD
Imatinib—ABCB1—lung—systemic scleroderma	0.000152	0.0013	CbGeAlD
Imatinib—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000113	0.000373	CcSEcCtD
Imatinib—Breast disorder—Methotrexate—systemic scleroderma	0.000113	0.000373	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000113	0.000372	CcSEcCtD
Imatinib—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000113	0.000372	CcSEcCtD
Imatinib—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000113	0.000371	CcSEcCtD
Imatinib—Hypersensitivity—Azathioprine—systemic scleroderma	0.000113	0.000371	CcSEcCtD
Imatinib—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000113	0.000371	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000112	0.000371	CcSEcCtD
Imatinib—Insomnia—Lisinopril—systemic scleroderma	0.000112	0.000369	CcSEcCtD
Imatinib—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000112	0.000369	CcSEcCtD
Imatinib—Paraesthesia—Lisinopril—systemic scleroderma	0.000111	0.000367	CcSEcCtD
Imatinib—Vomiting—Captopril—systemic scleroderma	0.000111	0.000367	CcSEcCtD
Imatinib—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000111	0.000365	CcSEcCtD
Imatinib—Dyspnoea—Lisinopril—systemic scleroderma	0.00011	0.000364	CcSEcCtD
Imatinib—Rash—Captopril—systemic scleroderma	0.00011	0.000364	CcSEcCtD
Imatinib—Dermatitis—Captopril—systemic scleroderma	0.00011	0.000363	CcSEcCtD
Imatinib—Somnolence—Lisinopril—systemic scleroderma	0.00011	0.000363	CcSEcCtD
Imatinib—Headache—Captopril—systemic scleroderma	0.00011	0.000361	CcSEcCtD
Imatinib—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000109	0.000361	CcSEcCtD
Imatinib—Dyspepsia—Lisinopril—systemic scleroderma	0.000109	0.000359	CcSEcCtD
Imatinib—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000109	0.000358	CcSEcCtD
Imatinib—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000109	0.000358	CcSEcCtD
Imatinib—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000109	0.000358	CcSEcCtD
Imatinib—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000109	0.000358	CcSEcCtD
Imatinib—Infection—Mycophenolate mofetil—systemic scleroderma	0.000108	0.000355	CcSEcCtD
Imatinib—Decreased appetite—Lisinopril—systemic scleroderma	0.000108	0.000355	CcSEcCtD
Imatinib—Eosinophilia—Methotrexate—systemic scleroderma	0.000107	0.000353	CcSEcCtD
Imatinib—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000107	0.000353	CcSEcCtD
Imatinib—Fatigue—Lisinopril—systemic scleroderma	0.000107	0.000352	CcSEcCtD
Imatinib—Shock—Mycophenolate mofetil—systemic scleroderma	0.000107	0.000352	CcSEcCtD
Imatinib—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000106	0.000351	CcSEcCtD
Imatinib—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000106	0.00035	CcSEcCtD
Imatinib—Hypersensitivity—Leflunomide—systemic scleroderma	0.000106	0.00035	CcSEcCtD
Imatinib—Pancreatitis—Methotrexate—systemic scleroderma	0.000106	0.000349	CcSEcCtD
Imatinib—Pain—Lisinopril—systemic scleroderma	0.000106	0.000349	CcSEcCtD
Imatinib—Constipation—Lisinopril—systemic scleroderma	0.000106	0.000349	CcSEcCtD
Imatinib—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000106	0.000349	CcSEcCtD
Imatinib—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000105	0.000348	CcSEcCtD
Imatinib—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000105	0.000346	CcSEcCtD
Imatinib—Diarrhoea—Azathioprine—systemic scleroderma	0.000104	0.000344	CcSEcCtD
Imatinib—Haemoglobin—Prednisone—systemic scleroderma	0.000104	0.000343	CcSEcCtD
Imatinib—Nausea—Captopril—systemic scleroderma	0.000104	0.000343	CcSEcCtD
Imatinib—Haemorrhage—Prednisone—systemic scleroderma	0.000104	0.000341	CcSEcCtD
Imatinib—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000104	0.000341	CcSEcCtD
Imatinib—Asthenia—Leflunomide—systemic scleroderma	0.000103	0.000341	CcSEcCtD
Imatinib—Pancytopenia—Methotrexate—systemic scleroderma	0.000103	0.000339	CcSEcCtD
Imatinib—Feeling abnormal—Lisinopril—systemic scleroderma	0.000102	0.000337	CcSEcCtD
Imatinib—Pruritus—Leflunomide—systemic scleroderma	0.000102	0.000336	CcSEcCtD
Imatinib—Connective tissue disorder—Prednisone—systemic scleroderma	0.000102	0.000335	CcSEcCtD
Imatinib—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000101	0.000334	CcSEcCtD
Imatinib—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000101	0.000334	CcSEcCtD
Imatinib—Neutropenia—Methotrexate—systemic scleroderma	0.000101	0.000333	CcSEcCtD
Imatinib—Dizziness—Azathioprine—systemic scleroderma	0.000101	0.000333	CcSEcCtD
Imatinib—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000101	0.000331	CcSEcCtD
Imatinib—Erectile dysfunction—Methotrexate—systemic scleroderma	9.96e-05	0.000328	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	9.89e-05	0.000326	CcSEcCtD
Imatinib—Photosensitivity reaction—Methotrexate—systemic scleroderma	9.87e-05	0.000325	CcSEcCtD
Imatinib—Asthenia—Mycophenolic acid—systemic scleroderma	9.87e-05	0.000325	CcSEcCtD
Imatinib—Diarrhoea—Leflunomide—systemic scleroderma	9.87e-05	0.000325	CcSEcCtD
Imatinib—Urticaria—Lisinopril—systemic scleroderma	9.85e-05	0.000324	CcSEcCtD
Imatinib—Insomnia—Mycophenolate mofetil—systemic scleroderma	9.82e-05	0.000324	CcSEcCtD
Imatinib—Abdominal pain—Lisinopril—systemic scleroderma	9.8e-05	0.000323	CcSEcCtD
Imatinib—Body temperature increased—Lisinopril—systemic scleroderma	9.8e-05	0.000323	CcSEcCtD
Imatinib—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	9.75e-05	0.000321	CcSEcCtD
Imatinib—Pruritus—Mycophenolic acid—systemic scleroderma	9.73e-05	0.000321	CcSEcCtD
Imatinib—Vomiting—Azathioprine—systemic scleroderma	9.71e-05	0.00032	CcSEcCtD
Imatinib—Pneumonia—Methotrexate—systemic scleroderma	9.7e-05	0.00032	CcSEcCtD
Imatinib—Eye disorder—Prednisone—systemic scleroderma	9.68e-05	0.000319	CcSEcCtD
Imatinib—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	9.68e-05	0.000319	CcSEcCtD
Imatinib—Somnolence—Mycophenolate mofetil—systemic scleroderma	9.65e-05	0.000318	CcSEcCtD
Imatinib—Infestation—Methotrexate—systemic scleroderma	9.64e-05	0.000318	CcSEcCtD
Imatinib—Infestation NOS—Methotrexate—systemic scleroderma	9.64e-05	0.000318	CcSEcCtD
Imatinib—Rash—Azathioprine—systemic scleroderma	9.63e-05	0.000317	CcSEcCtD
Imatinib—Dermatitis—Azathioprine—systemic scleroderma	9.62e-05	0.000317	CcSEcCtD
Imatinib—Depression—Methotrexate—systemic scleroderma	9.62e-05	0.000317	CcSEcCtD
Imatinib—Flushing—Prednisone—systemic scleroderma	9.62e-05	0.000317	CcSEcCtD
Imatinib—Headache—Azathioprine—systemic scleroderma	9.57e-05	0.000315	CcSEcCtD
Imatinib—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	9.56e-05	0.000315	CcSEcCtD
Imatinib—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	9.56e-05	0.000315	CcSEcCtD
Imatinib—Dizziness—Leflunomide—systemic scleroderma	9.54e-05	0.000314	CcSEcCtD
Imatinib—Renal failure—Methotrexate—systemic scleroderma	9.48e-05	0.000312	CcSEcCtD
Imatinib—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	9.44e-05	0.000311	CcSEcCtD
Imatinib—Diarrhoea—Mycophenolic acid—systemic scleroderma	9.41e-05	0.00031	CcSEcCtD
Imatinib—Stomatitis—Methotrexate—systemic scleroderma	9.4e-05	0.00031	CcSEcCtD
Imatinib—Angiopathy—Prednisone—systemic scleroderma	9.4e-05	0.00031	CcSEcCtD
Imatinib—Conjunctivitis—Methotrexate—systemic scleroderma	9.38e-05	0.000309	CcSEcCtD
Imatinib—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	9.37e-05	0.000309	CcSEcCtD
Imatinib—Immune system disorder—Prednisone—systemic scleroderma	9.36e-05	0.000308	CcSEcCtD
Imatinib—Constipation—Mycophenolate mofetil—systemic scleroderma	9.29e-05	0.000306	CcSEcCtD
Imatinib—Pain—Mycophenolate mofetil—systemic scleroderma	9.29e-05	0.000306	CcSEcCtD
Imatinib—Arrhythmia—Prednisone—systemic scleroderma	9.26e-05	0.000305	CcSEcCtD
Imatinib—Sweating—Methotrexate—systemic scleroderma	9.25e-05	0.000305	CcSEcCtD
Imatinib—Haematuria—Methotrexate—systemic scleroderma	9.2e-05	0.000303	CcSEcCtD
Imatinib—Vomiting—Leflunomide—systemic scleroderma	9.17e-05	0.000302	CcSEcCtD
Imatinib—Alopecia—Prednisone—systemic scleroderma	9.15e-05	0.000302	CcSEcCtD
Imatinib—Hypersensitivity—Lisinopril—systemic scleroderma	9.13e-05	0.000301	CcSEcCtD
Imatinib—Hepatobiliary disease—Methotrexate—systemic scleroderma	9.12e-05	0.000301	CcSEcCtD
Imatinib—Dizziness—Mycophenolic acid—systemic scleroderma	9.1e-05	0.0003	CcSEcCtD
Imatinib—Epistaxis—Methotrexate—systemic scleroderma	9.1e-05	0.0003	CcSEcCtD
Imatinib—Rash—Leflunomide—systemic scleroderma	9.09e-05	0.0003	CcSEcCtD
Imatinib—Dermatitis—Leflunomide—systemic scleroderma	9.09e-05	0.000299	CcSEcCtD
Imatinib—Mental disorder—Prednisone—systemic scleroderma	9.08e-05	0.000299	CcSEcCtD
Imatinib—Nausea—Azathioprine—systemic scleroderma	9.07e-05	0.000299	CcSEcCtD
Imatinib—Headache—Leflunomide—systemic scleroderma	9.04e-05	0.000298	CcSEcCtD
Imatinib—Erythema—Prednisone—systemic scleroderma	9.02e-05	0.000297	CcSEcCtD
Imatinib—Malnutrition—Prednisone—systemic scleroderma	9.02e-05	0.000297	CcSEcCtD
Imatinib—Agranulocytosis—Methotrexate—systemic scleroderma	9e-05	0.000297	CcSEcCtD
Imatinib—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	8.95e-05	0.000295	CcSEcCtD
Imatinib—Asthenia—Lisinopril—systemic scleroderma	8.89e-05	0.000293	CcSEcCtD
Imatinib—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	8.88e-05	0.000293	CcSEcCtD
Imatinib—Pruritus—Lisinopril—systemic scleroderma	8.77e-05	0.000289	CcSEcCtD
Imatinib—Vomiting—Mycophenolic acid—systemic scleroderma	8.75e-05	0.000288	CcSEcCtD
Imatinib—Haemoglobin—Methotrexate—systemic scleroderma	8.7e-05	0.000287	CcSEcCtD
Imatinib—Rash—Mycophenolic acid—systemic scleroderma	8.68e-05	0.000286	CcSEcCtD
Imatinib—Dermatitis—Mycophenolic acid—systemic scleroderma	8.67e-05	0.000286	CcSEcCtD
Imatinib—Hepatitis—Methotrexate—systemic scleroderma	8.66e-05	0.000285	CcSEcCtD
Imatinib—Haemorrhage—Methotrexate—systemic scleroderma	8.66e-05	0.000285	CcSEcCtD
Imatinib—Urticaria—Mycophenolate mofetil—systemic scleroderma	8.63e-05	0.000284	CcSEcCtD
Imatinib—Headache—Mycophenolic acid—systemic scleroderma	8.62e-05	0.000284	CcSEcCtD
Imatinib—Pharyngitis—Methotrexate—systemic scleroderma	8.59e-05	0.000283	CcSEcCtD
Imatinib—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	8.58e-05	0.000283	CcSEcCtD
Imatinib—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	8.58e-05	0.000283	CcSEcCtD
Imatinib—Nausea—Leflunomide—systemic scleroderma	8.57e-05	0.000282	CcSEcCtD
Imatinib—Urinary tract disorder—Methotrexate—systemic scleroderma	8.55e-05	0.000282	CcSEcCtD
Imatinib—Vision blurred—Prednisone—systemic scleroderma	8.5e-05	0.00028	CcSEcCtD
Imatinib—Urethral disorder—Methotrexate—systemic scleroderma	8.49e-05	0.00028	CcSEcCtD
Imatinib—Diarrhoea—Lisinopril—systemic scleroderma	8.48e-05	0.000279	CcSEcCtD
Imatinib—Ill-defined disorder—Prednisone—systemic scleroderma	8.37e-05	0.000276	CcSEcCtD
Imatinib—Anaemia—Prednisone—systemic scleroderma	8.34e-05	0.000275	CcSEcCtD
Imatinib—Angioedema—Prednisone—systemic scleroderma	8.24e-05	0.000272	CcSEcCtD
Imatinib—Dizziness—Lisinopril—systemic scleroderma	8.2e-05	0.00027	CcSEcCtD
Imatinib—Erythema multiforme—Methotrexate—systemic scleroderma	8.19e-05	0.00027	CcSEcCtD
Imatinib—Nausea—Mycophenolic acid—systemic scleroderma	8.17e-05	0.000269	CcSEcCtD
Imatinib—Malaise—Prednisone—systemic scleroderma	8.13e-05	0.000268	CcSEcCtD
Imatinib—Vertigo—Prednisone—systemic scleroderma	8.1e-05	0.000267	CcSEcCtD
Imatinib—Eye disorder—Methotrexate—systemic scleroderma	8.09e-05	0.000267	CcSEcCtD
Imatinib—Syncope—Prednisone—systemic scleroderma	8.09e-05	0.000267	CcSEcCtD
Imatinib—Tinnitus—Methotrexate—systemic scleroderma	8.07e-05	0.000266	CcSEcCtD
Imatinib—Cardiac disorder—Methotrexate—systemic scleroderma	8.04e-05	0.000265	CcSEcCtD
Imatinib—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	8e-05	0.000264	CcSEcCtD
Imatinib—Loss of consciousness—Prednisone—systemic scleroderma	7.93e-05	0.000261	CcSEcCtD
Imatinib—Vomiting—Lisinopril—systemic scleroderma	7.88e-05	0.00026	CcSEcCtD
Imatinib—Angiopathy—Methotrexate—systemic scleroderma	7.86e-05	0.000259	CcSEcCtD
Imatinib—Immune system disorder—Methotrexate—systemic scleroderma	7.82e-05	0.000258	CcSEcCtD
Imatinib—Rash—Lisinopril—systemic scleroderma	7.81e-05	0.000257	CcSEcCtD
Imatinib—Convulsion—Prednisone—systemic scleroderma	7.81e-05	0.000257	CcSEcCtD
Imatinib—Dermatitis—Lisinopril—systemic scleroderma	7.81e-05	0.000257	CcSEcCtD
Imatinib—Mediastinal disorder—Methotrexate—systemic scleroderma	7.8e-05	0.000257	CcSEcCtD
Imatinib—Asthenia—Mycophenolate mofetil—systemic scleroderma	7.79e-05	0.000257	CcSEcCtD
Imatinib—Hypertension—Prednisone—systemic scleroderma	7.79e-05	0.000257	CcSEcCtD
Imatinib—Chills—Methotrexate—systemic scleroderma	7.77e-05	0.000256	CcSEcCtD
Imatinib—Headache—Lisinopril—systemic scleroderma	7.76e-05	0.000256	CcSEcCtD
Imatinib—Pruritus—Mycophenolate mofetil—systemic scleroderma	7.68e-05	0.000253	CcSEcCtD
Imatinib—Arthralgia—Prednisone—systemic scleroderma	7.68e-05	0.000253	CcSEcCtD
Imatinib—Myalgia—Prednisone—systemic scleroderma	7.68e-05	0.000253	CcSEcCtD
Imatinib—Anxiety—Prednisone—systemic scleroderma	7.65e-05	0.000252	CcSEcCtD
Imatinib—Alopecia—Methotrexate—systemic scleroderma	7.65e-05	0.000252	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	7.63e-05	0.000251	CcSEcCtD
Imatinib—Discomfort—Prednisone—systemic scleroderma	7.59e-05	0.00025	CcSEcCtD
Imatinib—Mental disorder—Methotrexate—systemic scleroderma	7.59e-05	0.00025	CcSEcCtD
Imatinib—Malnutrition—Methotrexate—systemic scleroderma	7.54e-05	0.000248	CcSEcCtD
Imatinib—Erythema—Methotrexate—systemic scleroderma	7.54e-05	0.000248	CcSEcCtD
Imatinib—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	7.43e-05	0.000245	CcSEcCtD
Imatinib—Dysgeusia—Methotrexate—systemic scleroderma	7.38e-05	0.000243	CcSEcCtD
Imatinib—Nausea—Lisinopril—systemic scleroderma	7.36e-05	0.000243	CcSEcCtD
Imatinib—Oedema—Prednisone—systemic scleroderma	7.36e-05	0.000243	CcSEcCtD
Imatinib—Anaphylactic shock—Prednisone—systemic scleroderma	7.36e-05	0.000243	CcSEcCtD
Imatinib—Infection—Prednisone—systemic scleroderma	7.31e-05	0.000241	CcSEcCtD
Imatinib—Back pain—Methotrexate—systemic scleroderma	7.29e-05	0.00024	CcSEcCtD
Imatinib—Shock—Prednisone—systemic scleroderma	7.24e-05	0.000239	CcSEcCtD
Imatinib—Nervous system disorder—Prednisone—systemic scleroderma	7.22e-05	0.000238	CcSEcCtD
Imatinib—Tachycardia—Prednisone—systemic scleroderma	7.18e-05	0.000237	CcSEcCtD
Imatinib—Dizziness—Mycophenolate mofetil—systemic scleroderma	7.18e-05	0.000237	CcSEcCtD
Imatinib—Skin disorder—Prednisone—systemic scleroderma	7.15e-05	0.000236	CcSEcCtD
Imatinib—Hyperhidrosis—Prednisone—systemic scleroderma	7.12e-05	0.000234	CcSEcCtD
Imatinib—Vision blurred—Methotrexate—systemic scleroderma	7.1e-05	0.000234	CcSEcCtD
Imatinib—Anorexia—Prednisone—systemic scleroderma	7.02e-05	0.000231	CcSEcCtD
Imatinib—Ill-defined disorder—Methotrexate—systemic scleroderma	6.99e-05	0.00023	CcSEcCtD
Imatinib—Anaemia—Methotrexate—systemic scleroderma	6.97e-05	0.00023	CcSEcCtD
Imatinib—Vomiting—Mycophenolate mofetil—systemic scleroderma	6.9e-05	0.000228	CcSEcCtD
Imatinib—Rash—Mycophenolate mofetil—systemic scleroderma	6.85e-05	0.000226	CcSEcCtD
Imatinib—Dermatitis—Mycophenolate mofetil—systemic scleroderma	6.84e-05	0.000225	CcSEcCtD
Imatinib—Headache—Mycophenolate mofetil—systemic scleroderma	6.8e-05	0.000224	CcSEcCtD
Imatinib—Malaise—Methotrexate—systemic scleroderma	6.8e-05	0.000224	CcSEcCtD
Imatinib—Vertigo—Methotrexate—systemic scleroderma	6.77e-05	0.000223	CcSEcCtD
Imatinib—Leukopenia—Methotrexate—systemic scleroderma	6.75e-05	0.000222	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Prednisone—systemic scleroderma	6.71e-05	0.000221	CcSEcCtD
Imatinib—Insomnia—Prednisone—systemic scleroderma	6.66e-05	0.000219	CcSEcCtD
Imatinib—Paraesthesia—Prednisone—systemic scleroderma	6.61e-05	0.000218	CcSEcCtD
Imatinib—Cough—Methotrexate—systemic scleroderma	6.58e-05	0.000217	CcSEcCtD
Imatinib—Convulsion—Methotrexate—systemic scleroderma	6.53e-05	0.000215	CcSEcCtD
Imatinib—PDGFRB—Adaptive Immune System—BLK—systemic scleroderma	6.5e-05	0.000665	CbGpPWpGaD
Imatinib—ABL1—DNA Damage Response (only ATM dependent)—TGFB1—systemic scleroderma	6.5e-05	0.000665	CbGpPWpGaD
Imatinib—Dyspepsia—Prednisone—systemic scleroderma	6.48e-05	0.000214	CcSEcCtD
Imatinib—Nausea—Mycophenolate mofetil—systemic scleroderma	6.45e-05	0.000213	CcSEcCtD
Imatinib—ALB—Selenium Micronutrient Network—CCL2—systemic scleroderma	6.44e-05	0.000659	CbGpPWpGaD
Imatinib—Arthralgia—Methotrexate—systemic scleroderma	6.42e-05	0.000211	CcSEcCtD
Imatinib—Myalgia—Methotrexate—systemic scleroderma	6.42e-05	0.000211	CcSEcCtD
Imatinib—Chest pain—Methotrexate—systemic scleroderma	6.42e-05	0.000211	CcSEcCtD
Imatinib—Decreased appetite—Prednisone—systemic scleroderma	6.4e-05	0.000211	CcSEcCtD
Imatinib—KIT—Disease—TGFBI—systemic scleroderma	6.37e-05	0.000652	CbGpPWpGaD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	6.37e-05	0.00021	CcSEcCtD
Imatinib—CA1—Metabolism—HSPG2—systemic scleroderma	6.35e-05	0.00065	CbGpPWpGaD
Imatinib—Fatigue—Prednisone—systemic scleroderma	6.35e-05	0.000209	CcSEcCtD
Imatinib—Discomfort—Methotrexate—systemic scleroderma	6.34e-05	0.000209	CcSEcCtD
Imatinib—Constipation—Prednisone—systemic scleroderma	6.29e-05	0.000207	CcSEcCtD
Imatinib—KIT—Adaptive Immune System—CTLA4—systemic scleroderma	6.25e-05	0.000639	CbGpPWpGaD
Imatinib—LCK—Cytokine Signaling in Immune system—IL1A—systemic scleroderma	6.21e-05	0.000635	CbGpPWpGaD
Imatinib—Confusional state—Methotrexate—systemic scleroderma	6.2e-05	0.000204	CcSEcCtD
Imatinib—ALB—Folate Metabolism—IL1B—systemic scleroderma	6.15e-05	0.000629	CbGpPWpGaD
Imatinib—Anaphylactic shock—Methotrexate—systemic scleroderma	6.15e-05	0.000203	CcSEcCtD
Imatinib—Infection—Methotrexate—systemic scleroderma	6.11e-05	0.000201	CcSEcCtD
Imatinib—PTGS1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	6.09e-05	0.000623	CbGpPWpGaD
Imatinib—PDGFRB—MAPK Signaling Pathway—IL1B—systemic scleroderma	6.07e-05	0.000621	CbGpPWpGaD
Imatinib—Feeling abnormal—Prednisone—systemic scleroderma	6.07e-05	0.0002	CcSEcCtD
Imatinib—PDGFRA—Disease—TGFBI—systemic scleroderma	6.03e-05	0.000617	CbGpPWpGaD
Imatinib—Nervous system disorder—Methotrexate—systemic scleroderma	6.03e-05	0.000199	CcSEcCtD
Imatinib—Thrombocytopenia—Methotrexate—systemic scleroderma	6.02e-05	0.000198	CcSEcCtD
Imatinib—Gastrointestinal pain—Prednisone—systemic scleroderma	6.02e-05	0.000198	CcSEcCtD
Imatinib—LCK—Adaptive Immune System—CSK—systemic scleroderma	6e-05	0.000614	CbGpPWpGaD
Imatinib—Skin disorder—Methotrexate—systemic scleroderma	5.98e-05	0.000197	CcSEcCtD
Imatinib—Hyperhidrosis—Methotrexate—systemic scleroderma	5.95e-05	0.000196	CcSEcCtD
Imatinib—PDGFRB—Disease—SMAD7—systemic scleroderma	5.94e-05	0.000608	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—CTLA4—systemic scleroderma	5.91e-05	0.000605	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—ITGAM—systemic scleroderma	5.88e-05	0.000601	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—CD247—systemic scleroderma	5.88e-05	0.000601	CbGpPWpGaD
Imatinib—Anorexia—Methotrexate—systemic scleroderma	5.86e-05	0.000193	CcSEcCtD
Imatinib—Urticaria—Prednisone—systemic scleroderma	5.85e-05	0.000193	CcSEcCtD
Imatinib—Abdominal pain—Prednisone—systemic scleroderma	5.82e-05	0.000192	CcSEcCtD
Imatinib—Body temperature increased—Prednisone—systemic scleroderma	5.82e-05	0.000192	CcSEcCtD
Imatinib—Hypotension—Methotrexate—systemic scleroderma	5.75e-05	0.000189	CcSEcCtD
Imatinib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	5.74e-05	0.000587	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—CD247—systemic scleroderma	5.64e-05	0.000577	CbGpPWpGaD
Imatinib—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	5.6e-05	0.000185	CcSEcCtD
Imatinib—CA9—Metabolism—HSPG2—systemic scleroderma	5.59e-05	0.000571	CbGpPWpGaD
Imatinib—Insomnia—Methotrexate—systemic scleroderma	5.56e-05	0.000183	CcSEcCtD
Imatinib—Paraesthesia—Methotrexate—systemic scleroderma	5.52e-05	0.000182	CcSEcCtD
Imatinib—LCK—Innate Immune System—TNFAIP3—systemic scleroderma	5.5e-05	0.000563	CbGpPWpGaD
Imatinib—ABL2—Developmental Biology—TGFB1—systemic scleroderma	5.5e-05	0.000562	CbGpPWpGaD
Imatinib—Dyspnoea—Methotrexate—systemic scleroderma	5.48e-05	0.000181	CcSEcCtD
Imatinib—Somnolence—Methotrexate—systemic scleroderma	5.47e-05	0.00018	CcSEcCtD
Imatinib—PDGFRB—Disease—TGFBI—systemic scleroderma	5.44e-05	0.000556	CbGpPWpGaD
Imatinib—Hypersensitivity—Prednisone—systemic scleroderma	5.42e-05	0.000179	CcSEcCtD
Imatinib—Dyspepsia—Methotrexate—systemic scleroderma	5.41e-05	0.000178	CcSEcCtD
Imatinib—Decreased appetite—Methotrexate—systemic scleroderma	5.35e-05	0.000176	CcSEcCtD
Imatinib—PDGFRB—Adaptive Immune System—CTLA4—systemic scleroderma	5.33e-05	0.000545	CbGpPWpGaD
Imatinib—KIT—Immune System—CSK—systemic scleroderma	5.32e-05	0.000544	CbGpPWpGaD
Imatinib—Gastrointestinal disorder—Methotrexate—systemic scleroderma	5.31e-05	0.000175	CcSEcCtD
Imatinib—Fatigue—Methotrexate—systemic scleroderma	5.3e-05	0.000175	CcSEcCtD
Imatinib—LCK—Signaling by SCF-KIT—MMP9—systemic scleroderma	5.29e-05	0.000541	CbGpPWpGaD
Imatinib—Asthenia—Prednisone—systemic scleroderma	5.28e-05	0.000174	CcSEcCtD
Imatinib—CA3—Metabolism—NOS3—systemic scleroderma	5.26e-05	0.000538	CbGpPWpGaD
Imatinib—Pain—Methotrexate—systemic scleroderma	5.26e-05	0.000173	CcSEcCtD
Imatinib—KIT—Immune System—IRF5—systemic scleroderma	5.23e-05	0.000535	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—BLK—systemic scleroderma	5.22e-05	0.000534	CbGpPWpGaD
Imatinib—Pruritus—Prednisone—systemic scleroderma	5.21e-05	0.000172	CcSEcCtD
Imatinib—NTRK1—Signaling Pathways—RHOB—systemic scleroderma	5.15e-05	0.000527	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—HLA-DQB1—systemic scleroderma	5.14e-05	0.000526	CbGpPWpGaD
Imatinib—KIT—Disease—HSPG2—systemic scleroderma	5.08e-05	0.00052	CbGpPWpGaD
Imatinib—Feeling abnormal—Methotrexate—systemic scleroderma	5.07e-05	0.000167	CcSEcCtD
Imatinib—Diarrhoea—Prednisone—systemic scleroderma	5.04e-05	0.000166	CcSEcCtD
Imatinib—PDGFRA—Immune System—CSK—systemic scleroderma	5.03e-05	0.000515	CbGpPWpGaD
Imatinib—Gastrointestinal pain—Methotrexate—systemic scleroderma	5.03e-05	0.000166	CcSEcCtD
Imatinib—CA2—Metabolism—CTGF—systemic scleroderma	5.02e-05	0.000514	CbGpPWpGaD
Imatinib—KIT—Immune System—ITGAM—systemic scleroderma	5e-05	0.000511	CbGpPWpGaD
Imatinib—KIT—Immune System—IRF8—systemic scleroderma	5e-05	0.000511	CbGpPWpGaD
Imatinib—KIT—Immune System—CD247—systemic scleroderma	5e-05	0.000511	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IRF5—systemic scleroderma	4.95e-05	0.000506	CbGpPWpGaD
Imatinib—KIT—Disease—CSK—systemic scleroderma	4.91e-05	0.000502	CbGpPWpGaD
Imatinib—ALB—Selenium Micronutrient Network—IL1B—systemic scleroderma	4.89e-05	0.0005	CbGpPWpGaD
Imatinib—Urticaria—Methotrexate—systemic scleroderma	4.89e-05	0.000161	CcSEcCtD
Imatinib—KIT—Signaling Pathways—SMAD7—systemic scleroderma	4.88e-05	0.000499	CbGpPWpGaD
Imatinib—ALB—Hemostasis—SELP—systemic scleroderma	4.88e-05	0.000499	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—HLA-DQB1—systemic scleroderma	4.87e-05	0.000498	CbGpPWpGaD
Imatinib—Dizziness—Prednisone—systemic scleroderma	4.87e-05	0.00016	CcSEcCtD
Imatinib—Body temperature increased—Methotrexate—systemic scleroderma	4.86e-05	0.00016	CcSEcCtD
Imatinib—Abdominal pain—Methotrexate—systemic scleroderma	4.86e-05	0.00016	CcSEcCtD
Imatinib—NTRK1—Signaling Pathways—HSPG2—systemic scleroderma	4.86e-05	0.000497	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—CD40LG—systemic scleroderma	4.86e-05	0.000497	CbGpPWpGaD
Imatinib—CA1—Metabolism—CTGF—systemic scleroderma	4.82e-05	0.000492	CbGpPWpGaD
Imatinib—PDGFRA—Disease—HSPG2—systemic scleroderma	4.81e-05	0.000492	CbGpPWpGaD
Imatinib—LCK—Disease—SMAD7—systemic scleroderma	4.77e-05	0.000488	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IRF8—systemic scleroderma	4.73e-05	0.000484	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CD247—systemic scleroderma	4.73e-05	0.000484	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—ITGAM—systemic scleroderma	4.73e-05	0.000484	CbGpPWpGaD
Imatinib—PDGFRA—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	4.73e-05	0.000483	CbGpPWpGaD
Imatinib—PDGFRB—MAPK Signaling Pathway—TGFB1—systemic scleroderma	4.72e-05	0.000483	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—CSK—systemic scleroderma	4.69e-05	0.00048	CbGpPWpGaD
Imatinib—KIT—Immune System—TNFAIP3—systemic scleroderma	4.68e-05	0.000479	CbGpPWpGaD
Imatinib—Vomiting—Prednisone—systemic scleroderma	4.68e-05	0.000154	CcSEcCtD
Imatinib—ABCB1—Allograft Rejection—IL1B—systemic scleroderma	4.67e-05	0.000477	CbGpPWpGaD
Imatinib—PDGFRA—Disease—CSK—systemic scleroderma	4.65e-05	0.000475	CbGpPWpGaD
Imatinib—Rash—Prednisone—systemic scleroderma	4.64e-05	0.000153	CcSEcCtD
Imatinib—Dermatitis—Prednisone—systemic scleroderma	4.64e-05	0.000153	CcSEcCtD
Imatinib—KIT—Immune System—BLK—systemic scleroderma	4.63e-05	0.000473	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—SMAD7—systemic scleroderma	4.62e-05	0.000472	CbGpPWpGaD
Imatinib—KIT—Disease—CD247—systemic scleroderma	4.62e-05	0.000472	CbGpPWpGaD
Imatinib—PTGS1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	4.62e-05	0.000472	CbGpPWpGaD
Imatinib—Headache—Prednisone—systemic scleroderma	4.61e-05	0.000152	CcSEcCtD
Imatinib—PDGFRA—Adaptive Immune System—CD40LG—systemic scleroderma	4.6e-05	0.00047	CbGpPWpGaD
Imatinib—ALB—Hemostasis—RHOB—systemic scleroderma	4.56e-05	0.000466	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CSK—systemic scleroderma	4.54e-05	0.000464	CbGpPWpGaD
Imatinib—Hypersensitivity—Methotrexate—systemic scleroderma	4.53e-05	0.000149	CcSEcCtD
Imatinib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	4.46e-05	0.000456	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IRF5—systemic scleroderma	4.46e-05	0.000456	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—TNFAIP3—systemic scleroderma	4.43e-05	0.000453	CbGpPWpGaD
Imatinib—ABL1—Immune System—CSK—systemic scleroderma	4.42e-05	0.000452	CbGpPWpGaD
Imatinib—Asthenia—Methotrexate—systemic scleroderma	4.41e-05	0.000145	CcSEcCtD
Imatinib—ABL1—Axon guidance—MMP2—systemic scleroderma	4.39e-05	0.000449	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—HLA-DQB1—systemic scleroderma	4.39e-05	0.000449	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—BLK—systemic scleroderma	4.38e-05	0.000448	CbGpPWpGaD
Imatinib—Nausea—Prednisone—systemic scleroderma	4.37e-05	0.000144	CcSEcCtD
Imatinib—PDGFRA—Disease—CD247—systemic scleroderma	4.37e-05	0.000447	CbGpPWpGaD
Imatinib—LCK—Disease—TGFBI—systemic scleroderma	4.36e-05	0.000446	CbGpPWpGaD
Imatinib—Pruritus—Methotrexate—systemic scleroderma	4.35e-05	0.000143	CcSEcCtD
Imatinib—ABL1—Immune System—IRF5—systemic scleroderma	4.35e-05	0.000445	CbGpPWpGaD
Imatinib—PDGFRB—Disease—HSPG2—systemic scleroderma	4.34e-05	0.000443	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—CTLA4—systemic scleroderma	4.28e-05	0.000437	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IRF8—systemic scleroderma	4.26e-05	0.000436	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—ITGAM—systemic scleroderma	4.26e-05	0.000436	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CD247—systemic scleroderma	4.26e-05	0.000436	CbGpPWpGaD
Imatinib—CA9—Metabolism—CTGF—systemic scleroderma	4.23e-05	0.000433	CbGpPWpGaD
Imatinib—Diarrhoea—Methotrexate—systemic scleroderma	4.21e-05	0.000139	CcSEcCtD
Imatinib—PDGFRB—Disease—CSK—systemic scleroderma	4.19e-05	0.000428	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—SMAD7—systemic scleroderma	4.16e-05	0.000426	CbGpPWpGaD
Imatinib—ABL1—Immune System—IRF8—systemic scleroderma	4.16e-05	0.000425	CbGpPWpGaD
Imatinib—ABL1—Immune System—ITGAM—systemic scleroderma	4.16e-05	0.000425	CbGpPWpGaD
Imatinib—ABL1—Immune System—CD247—systemic scleroderma	4.16e-05	0.000425	CbGpPWpGaD
Imatinib—ABL1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	4.15e-05	0.000424	CbGpPWpGaD
Imatinib—ALB—Hemostasis—CSK—systemic scleroderma	4.15e-05	0.000424	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—CD40LG—systemic scleroderma	4.14e-05	0.000424	CbGpPWpGaD
Imatinib—ALB—Platelet degranulation—TGFB1—systemic scleroderma	4.1e-05	0.000419	CbGpPWpGaD
Imatinib—Dizziness—Methotrexate—systemic scleroderma	4.07e-05	0.000134	CcSEcCtD
Imatinib—PDGFRB—Immune System—TNFAIP3—systemic scleroderma	3.99e-05	0.000408	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—MMP1—systemic scleroderma	3.97e-05	0.000406	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—BLK—systemic scleroderma	3.95e-05	0.000403	CbGpPWpGaD
Imatinib—PDGFRB—Disease—CD247—systemic scleroderma	3.94e-05	0.000403	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	3.91e-05	0.0004	CbGpPWpGaD
Imatinib—Vomiting—Methotrexate—systemic scleroderma	3.91e-05	0.000129	CcSEcCtD
Imatinib—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—systemic scleroderma	3.9e-05	0.000399	CbGpPWpGaD
Imatinib—ALB—Hemostasis—ITGAM—systemic scleroderma	3.9e-05	0.000399	CbGpPWpGaD
Imatinib—ABL1—Immune System—TNFAIP3—systemic scleroderma	3.89e-05	0.000398	CbGpPWpGaD
Imatinib—Rash—Methotrexate—systemic scleroderma	3.88e-05	0.000128	CcSEcCtD
Imatinib—Dermatitis—Methotrexate—systemic scleroderma	3.87e-05	0.000128	CcSEcCtD
Imatinib—Headache—Methotrexate—systemic scleroderma	3.85e-05	0.000127	CcSEcCtD
Imatinib—ABL1—Immune System—BLK—systemic scleroderma	3.84e-05	0.000393	CbGpPWpGaD
Imatinib—KIT—Immune System—CTLA4—systemic scleroderma	3.79e-05	0.000387	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—RHOB—systemic scleroderma	3.78e-05	0.000386	CbGpPWpGaD
Imatinib—Nausea—Methotrexate—systemic scleroderma	3.65e-05	0.00012	CcSEcCtD
Imatinib—LCK—Immune System—CSK—systemic scleroderma	3.64e-05	0.000372	CbGpPWpGaD
Imatinib—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	3.63e-05	0.000371	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CTLA4—systemic scleroderma	3.59e-05	0.000367	CbGpPWpGaD
Imatinib—LCK—Immune System—IRF5—systemic scleroderma	3.58e-05	0.000366	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—RHOB—systemic scleroderma	3.57e-05	0.000365	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—HSPG2—systemic scleroderma	3.56e-05	0.000364	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—HLA-DQB1—systemic scleroderma	3.52e-05	0.00036	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	3.51e-05	0.000359	CbGpPWpGaD
Imatinib—LCK—Disease—HSPG2—systemic scleroderma	3.48e-05	0.000356	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CSK—systemic scleroderma	3.44e-05	0.000352	CbGpPWpGaD
Imatinib—LCK—Immune System—IRF8—systemic scleroderma	3.42e-05	0.00035	CbGpPWpGaD
Imatinib—LCK—Immune System—ITGAM—systemic scleroderma	3.42e-05	0.00035	CbGpPWpGaD
Imatinib—LCK—Immune System—CD247—systemic scleroderma	3.42e-05	0.00035	CbGpPWpGaD
Imatinib—CA14—Metabolism—NOS3—systemic scleroderma	3.39e-05	0.000347	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—HSPG2—systemic scleroderma	3.37e-05	0.000345	CbGpPWpGaD
Imatinib—LCK—Disease—CSK—systemic scleroderma	3.36e-05	0.000344	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—SMAD7—systemic scleroderma	3.34e-05	0.000342	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—CD40LG—systemic scleroderma	3.33e-05	0.00034	CbGpPWpGaD
Imatinib—CA6—Metabolism—NOS3—systemic scleroderma	3.31e-05	0.000338	CbGpPWpGaD
Imatinib—ABL1—Axon guidance—MMP9—systemic scleroderma	3.3e-05	0.000337	CbGpPWpGaD
Imatinib—LCK—Hemostasis—MMP1—systemic scleroderma	3.27e-05	0.000334	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CSK—systemic scleroderma	3.25e-05	0.000333	CbGpPWpGaD
Imatinib—LCK—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	3.24e-05	0.000331	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CTLA4—systemic scleroderma	3.23e-05	0.00033	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—RHOB—systemic scleroderma	3.22e-05	0.000329	CbGpPWpGaD
Imatinib—LCK—Immune System—TNFAIP3—systemic scleroderma	3.2e-05	0.000328	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	3.2e-05	0.000327	CbGpPWpGaD
Imatinib—LCK—Immune System—BLK—systemic scleroderma	3.17e-05	0.000324	CbGpPWpGaD
Imatinib—LCK—Disease—CD247—systemic scleroderma	3.16e-05	0.000323	CbGpPWpGaD
Imatinib—ABL1—Immune System—CTLA4—systemic scleroderma	3.15e-05	0.000322	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—MMP2—systemic scleroderma	3.13e-05	0.00032	CbGpPWpGaD
Imatinib—KIT—Immune System—HLA-DQB1—systemic scleroderma	3.12e-05	0.000319	CbGpPWpGaD
Imatinib—CA7—Metabolism—NOS3—systemic scleroderma	3.09e-05	0.000316	CbGpPWpGaD
Imatinib—LCK—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	3.04e-05	0.000311	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—HSPG2—systemic scleroderma	3.04e-05	0.00031	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.96e-05	0.000303	CbGpPWpGaD
Imatinib—KIT—Immune System—IL1A—systemic scleroderma	2.96e-05	0.000303	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—HLA-DQB1—systemic scleroderma	2.95e-05	0.000302	CbGpPWpGaD
Imatinib—KIT—Immune System—CD40LG—systemic scleroderma	2.95e-05	0.000301	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CSK—systemic scleroderma	2.93e-05	0.0003	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—NOS3—systemic scleroderma	2.88e-05	0.000294	CbGpPWpGaD
Imatinib—CA12—Metabolism—NOS3—systemic scleroderma	2.86e-05	0.000292	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—HSPG2—systemic scleroderma	2.82e-05	0.000289	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IL1A—systemic scleroderma	2.81e-05	0.000287	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—HSPG2—systemic scleroderma	2.8e-05	0.000286	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—HSPG2—systemic scleroderma	2.79e-05	0.000286	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CD40LG—systemic scleroderma	2.79e-05	0.000285	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	2.74e-05	0.00028	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—HSPG2—systemic scleroderma	2.71e-05	0.000277	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—HLA-DQB1—systemic scleroderma	2.66e-05	0.000272	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.66e-05	0.000272	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—EDN1—systemic scleroderma	2.63e-05	0.000269	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—HSPG2—systemic scleroderma	2.6e-05	0.000266	CbGpPWpGaD
Imatinib—ABL1—Immune System—HLA-DQB1—systemic scleroderma	2.59e-05	0.000265	CbGpPWpGaD
Imatinib—LCK—Immune System—CTLA4—systemic scleroderma	2.59e-05	0.000265	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—RHOB—systemic scleroderma	2.58e-05	0.000264	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL1A—systemic scleroderma	2.53e-05	0.000258	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CD40LG—systemic scleroderma	2.51e-05	0.000257	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL1A—systemic scleroderma	2.46e-05	0.000252	CbGpPWpGaD
Imatinib—ABL1—Immune System—CD40LG—systemic scleroderma	2.45e-05	0.00025	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—HSPG2—systemic scleroderma	2.44e-05	0.000249	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.43e-05	0.000248	CbGpPWpGaD
Imatinib—LCK—Hemostasis—NOS3—systemic scleroderma	2.37e-05	0.000242	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—MMP9—systemic scleroderma	2.35e-05	0.000241	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CSK—systemic scleroderma	2.35e-05	0.000241	CbGpPWpGaD
Imatinib—CA2—Metabolism—NOS3—systemic scleroderma	2.19e-05	0.000224	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—CTGF—systemic scleroderma	2.14e-05	0.000219	CbGpPWpGaD
Imatinib—LCK—Immune System—HLA-DQB1—systemic scleroderma	2.14e-05	0.000218	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—CTGF—systemic scleroderma	2.12e-05	0.000217	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—CTGF—systemic scleroderma	2.12e-05	0.000216	CbGpPWpGaD
Imatinib—CA1—Metabolism—NOS3—systemic scleroderma	2.1e-05	0.000214	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.07e-05	0.000212	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—CTGF—systemic scleroderma	2.06e-05	0.00021	CbGpPWpGaD
Imatinib—LCK—Immune System—IL1A—systemic scleroderma	2.03e-05	0.000207	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—HSPG2—systemic scleroderma	2.02e-05	0.000207	CbGpPWpGaD
Imatinib—LCK—Immune System—CD40LG—systemic scleroderma	2.02e-05	0.000206	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—CTGF—systemic scleroderma	1.97e-05	0.000202	CbGpPWpGaD
Imatinib—ALB—Hemostasis—MMP1—systemic scleroderma	1.95e-05	0.0002	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—TGFB1—systemic scleroderma	1.94e-05	0.000198	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—EDN1—systemic scleroderma	1.93e-05	0.000197	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—TGFB1—systemic scleroderma	1.9e-05	0.000195	CbGpPWpGaD
Imatinib—CA9—Metabolism—NOS3—systemic scleroderma	1.84e-05	0.000188	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—EDN1—systemic scleroderma	1.82e-05	0.000187	CbGpPWpGaD
Imatinib—ALB—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	1.82e-05	0.000186	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—CCL2—systemic scleroderma	1.8e-05	0.000184	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	1.79e-05	0.000183	CbGpPWpGaD
Imatinib—ALB—Metabolism—HSPG2—systemic scleroderma	1.74e-05	0.000178	CbGpPWpGaD
Imatinib—KIT—Disease—NOS3—systemic scleroderma	1.68e-05	0.000171	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—EDN1—systemic scleroderma	1.64e-05	0.000168	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—NOS3—systemic scleroderma	1.6e-05	0.000164	CbGpPWpGaD
Imatinib—PDGFRA—Disease—NOS3—systemic scleroderma	1.59e-05	0.000162	CbGpPWpGaD
Imatinib—LCK—Hemostasis—TGFB1—systemic scleroderma	1.57e-05	0.00016	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—HSPG2—systemic scleroderma	1.56e-05	0.00016	CbGpPWpGaD
Imatinib—KIT—Immune System—IL1B—systemic scleroderma	1.55e-05	0.000158	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—CTGF—systemic scleroderma	1.53e-05	0.000157	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—HSPG2—systemic scleroderma	1.53e-05	0.000156	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IL1B—systemic scleroderma	1.46e-05	0.00015	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—HSPG2—systemic scleroderma	1.44e-05	0.000147	CbGpPWpGaD
Imatinib—PDGFRB—Disease—NOS3—systemic scleroderma	1.43e-05	0.000146	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—HSPG2—systemic scleroderma	1.43e-05	0.000146	CbGpPWpGaD
Imatinib—ALB—Hemostasis—NOS3—systemic scleroderma	1.42e-05	0.000145	CbGpPWpGaD
Imatinib—ALB—Metabolism—CTGF—systemic scleroderma	1.32e-05	0.000135	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—EDN1—systemic scleroderma	1.32e-05	0.000135	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL1B—systemic scleroderma	1.32e-05	0.000135	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CCL2—systemic scleroderma	1.32e-05	0.000135	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—MMP9—systemic scleroderma	1.29e-05	0.000131	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL1B—systemic scleroderma	1.28e-05	0.000131	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CCL2—systemic scleroderma	1.25e-05	0.000128	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—HSPG2—systemic scleroderma	1.22e-05	0.000125	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CTGF—systemic scleroderma	1.19e-05	0.000121	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—NOS3—systemic scleroderma	1.17e-05	0.00012	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CTGF—systemic scleroderma	1.16e-05	0.000118	CbGpPWpGaD
Imatinib—LCK—Disease—NOS3—systemic scleroderma	1.15e-05	0.000117	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CCL2—systemic scleroderma	1.12e-05	0.000115	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—NOS3—systemic scleroderma	1.11e-05	0.000114	CbGpPWpGaD
Imatinib—KIT—Disease—TGFB1—systemic scleroderma	1.11e-05	0.000113	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CTGF—systemic scleroderma	1.09e-05	0.000111	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CTGF—systemic scleroderma	1.08e-05	0.00011	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TGFB1—systemic scleroderma	1.06e-05	0.000108	CbGpPWpGaD
Imatinib—LCK—Immune System—IL1B—systemic scleroderma	1.06e-05	0.000108	CbGpPWpGaD
Imatinib—PDGFRA—Disease—TGFB1—systemic scleroderma	1.05e-05	0.000107	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—NOS3—systemic scleroderma	1e-05	0.000102	CbGpPWpGaD
Imatinib—PDGFRB—Disease—TGFB1—systemic scleroderma	9.46e-06	9.67e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MMP9—systemic scleroderma	9.42e-06	9.63e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—HSPG2—systemic scleroderma	9.4e-06	9.61e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TGFB1—systemic scleroderma	9.37e-06	9.58e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—NOS3—systemic scleroderma	9.31e-06	9.52e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CTGF—systemic scleroderma	9.23e-06	9.44e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—NOS3—systemic scleroderma	9.23e-06	9.44e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—NOS3—systemic scleroderma	9.22e-06	9.42e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CCL2—systemic scleroderma	9.02e-06	9.22e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—NOS3—systemic scleroderma	8.95e-06	9.15e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MMP9—systemic scleroderma	8.92e-06	9.12e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—NOS3—systemic scleroderma	8.59e-06	8.78e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—NOS3—systemic scleroderma	8.04e-06	8.22e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MMP9—systemic scleroderma	8.04e-06	8.22e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TGFB1—systemic scleroderma	7.77e-06	7.94e-05	CbGpPWpGaD
Imatinib—LCK—Disease—TGFB1—systemic scleroderma	7.59e-06	7.76e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TGFB1—systemic scleroderma	7.35e-06	7.52e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CTGF—systemic scleroderma	7.13e-06	7.29e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—NOS3—systemic scleroderma	6.67e-06	6.82e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TGFB1—systemic scleroderma	6.62e-06	6.77e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MMP9—systemic scleroderma	6.45e-06	6.59e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—NOS3—systemic scleroderma	5.75e-06	5.88e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TGFB1—systemic scleroderma	5.31e-06	5.43e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—NOS3—systemic scleroderma	5.16e-06	5.27e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—NOS3—systemic scleroderma	5.03e-06	5.15e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—NOS3—systemic scleroderma	4.74e-06	4.85e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—NOS3—systemic scleroderma	4.7e-06	4.81e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—NOS3—systemic scleroderma	4.02e-06	4.11e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—NOS3—systemic scleroderma	3.1e-06	3.17e-05	CbGpPWpGaD
